What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?

Journal of Neural Transmission, Supplement

Volumn , Issue 65, 2003, Pages 73-88

  Youdim, M B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; APOMORPHINE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EBSELEN; EPIGALLOCATECHIN GALLATE; IRON; IRON CHELATING AGENT; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; NEUROPROTECTIVE AGENT; NEUROTOXIN; PENICILLAMINE; QUINOLINOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; SCAVENGER; TRANSITION ELEMENT; UNCLASSIFIED DRUG; VK 28; DOPAMINE RECEPTOR STIMULATING AGENT; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ATAXIA; BLOOD BRAIN BARRIER; BRADYKINESIA; CELL LEVEL; CONFERENCE PAPER; DNA MICROARRAY; DOPAMINERGIC NERVE CELL; DRUG DESIGN; DRUG POTENCY; GENE EXPRESSION; GENE MUTATION; HUMAN; IN SITU HYBRIDIZATION; IRON METABOLISM; IRON RESPONSIVE ELEMENT; KNOCKOUT MOUSE; LIPID PEROXIDATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; UBIQUITINATION; WESTERN BLOTTING; WILSON DISEASE; ANIMAL; BRAIN; CELL DEATH; CHEMICALLY INDUCED DISORDER; GENETICS; METABOLISM; NERVE CELL; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CELL DEATH; DOPAMINE; DOPAMINE AGENTS; HUMANS; IRON; IRON CHELATING AGENTS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYNUCLEINS;

EID: 0141940629     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0643-3_5     Document Type: Conference Paper

References (80)

1. Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60: L23-29
2. Ben-Shachar D, Eshel G, Finberg JP, Youdim MBH (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444
3. Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim MBH (2002) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. J Neurochem (in press)
4. Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P, Becker G (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25: 901-904
5. Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79: 225-236
6. Borisenko GG, Kagan VE, Hsia CJ, Schor NF (2000) Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry 39: 3392-3400
7. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10-15
8. Cohen G (2001) Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 899: 112-120
9. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836
10. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M (1998) In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70: 2492-2499
11. Duda JE, Lee VM, Trojanowski JQ (2000) Neuropathology of synuclein aggregates. J Neurosci Res 61: 121-127
12. Eisenstein RS (2000) Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 20: 627-662
13. Ferger B, Spratt C, Teismann P, Seitz G, Kuschinsky K (1998) Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360: 155-163
14. Fernandez-Gonzalez A, Perez-Otano I, Morgan JI (2000) MPTP selectively induces haemoxygenase-1 expression in striatal astrocytes. Eur J Neurosci 12: 1573-1583
15. Fredriksson A, Schroder N, Eriksson P, Izquierdo I, Archer T (2001) Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Relat Disord 8: 97-105
16. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219-225
17. Gassen M, Gross A, Youdim MBH (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 13: 242-248
18. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 793: 793-807
19. Glinka YY, Youdim MBH (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopmine. Eur J Pharmacol 292: 329-332
20. Glinka Y, Tipton KF, Youdim MBH (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem 66: 2004-2010
21. Glinka Y, Tipton KF, Youdim MBH (1998) Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur J Pharmacol 351: 121-129
22. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 15: 15
23. Goto K, Mochizuki H, Imai H, Akiyama H, Mizuno Y (1996) An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res 724: 125-128
24. Grunblatt E, Mandel S, Berkuzki T, Youdim MBH (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14: 612-618
25. Grunblatt E, Mandel S, Maor G, Youdim MBH (2001a) Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J Neurochem 78: 1-12
26. Grunblatt E, Mandel S, Maor G, Youdim MBH (2001b) Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J Neurochem 77: 146-156
27. Hall S, Rutledge JN, Schallert T (1992) MRI, brain iron and experimental Parkinson's disease. J Neurol Sci 113: 198-208
28. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716
29. Han J, Cheng FC, Yang Z, Dryhurst G (1999) Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem 73: 1683-1695
30. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E (1999a) Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 274: 28849-28852
31. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999b) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10: 717-721
32. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 94: 7531-7536
33. Itazaki H, Kawasaki A, Matsuura M, Ueda M, Yonetani Y, Nakamura M (1988) Synthesis of 2,3-dihydro-1,4-benzodioxin derivatives. I. 2-substituted-5(and 6)-sulfamoyl-2,3-dihydro-1,4-benzodioxins. Chem Pharm Bull (Tokyo) 36: 3387-3403
34. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm [PD Sect] 2: 327-340
35. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 59: 1168-1171
36. Jellinger K (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140
37. Jenner P (1991) Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand [Suppl] 136: 6-15
38. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-170
39. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11: 211-213
40. Lan J, Jiang DH (1997a) Desferrixamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469-481
41. Lan J, Jiang DH (1997b) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104: 649-660
42. Langston JW (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47: S153-160
43. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, Switzer R, 3rd, Grinberg A, Love P, Tresser N, Rouault TA (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27: 209-214
44. Leibold EA, Gahring LC, Rogers SW (2001) Immunolocalization of iron regulatory protein expression in the murine central nervous system. Histochem Cell Biol 115: 195-203
45. Levites Y, Mandel S, Maor G, Youdim MBH (2001a) EGCG attenuates neuronal cell death in 6-OHDA and MPTP models of Parkinson's disease: possible gene targets. Neural Plast 8: 184
46. Levites Y, Youdim MBH, Maor G, Mandel S (2002a) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol 63: 21-29
47. Levites Y, Amit T, Mandel S, Youdim MBH (2002b) Green tea polyphenol (-)-epigallocatechin-3-gallate regulates secretion of non-amyloidogenic precursor protein via protein kinase C pathway. FASEB J (in press)
48. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S (2001b) Green tea polyphenol (-)-Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78: 1073-1082
49. Lin YL, Lin JK (1997) (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide- induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52: 465-472
50. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H (1997) Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 272: G1355-G1364
51. Linert W, Herdinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH (1996) Dopamine, 6-hydroxydopamine, iron, and oxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1316: 160-168
52. Lode HN, Bruchelt G, Rieth AG, Niethammer D (1990) Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Rad Res Commun 11: 153-158
53. Mandel S, Grunblatt E, Maor G, Youdim MBH (2002a) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27: 1231-1243
54. Mandel S, Grunblatt E, Youdim MBH (2002b) Genes and oxidative stress in Parkinsonism: cDNA microarray studies. Adv Neurol 91: 123-133
55. Mash DC, Pablo J, Buck BE, Sanchez-Ramos J, Weiner WJ (1991) Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp Neurol 114: 73-81
56. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41: 404-407
57. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 168: 251-253
58. Monteiro HP, Winterbourn CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38: 4177-4182
59. Moussaoui S, Obinu MC, Daniel N, Reibaud M, Blanchard V, Imperato A (2000) The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 166: 235-245
60. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660: 8-18
61. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20: 6048-6054
62. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, Wall RA (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett 60: 109-114
63. Pezzella A, d'Ischia M, Napolitano A, Misuraca G, Prota G (1997) Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. Med Chem 40: 2211-2216
64. Przedborski S, Chen Q, Vila M, Giasson BI, Djaldatti R, Vukosavic S, Souza JM, Jackson-Lewis VV, Lee VM, Ischiropoulos H (2001) Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 76: 637-640
65. Ramsay RR, Kowal AT, Johnson MK, Salach JI, Singer TP (1987) The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys 259: 645-649
66. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
67. Roghani M, Behzadi G (2001) Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res 892: 211-217
68. Seaton TA, Cooper JM, Schapira AH (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 777: 110-118
69. Shoham S, Youdim MBH (2000) Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 46: 743-760
70. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199-205
71. Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62: 134-146
72. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G (1999) Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol 277: G1240-1250
73. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276: 44284-44296
74. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74: 721-729
75. Warshawsky B, Hussain Z, Gregson DB, Alder R, Austin M, Bruckschwaiger D, Chagla AH, Daley J, Duhaime C, McGhie K, Pollett G, Potters H, Schiedel L (2000) Hospital-and community-based surveillance of methicillin-resistant Staphylococcus aureus: previous hospitalization is the major risk factor. Infect Control Hosp Epidemiol 21: 724-727
76. Yantiri F, Andersen JK (1999) The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. IUBMB Life 48: 139-141
77. Youdim MBH, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 8: 1-12
78. Youdim MBH (1985) Brain iron metabolism. Biochemical and behavioral aspects in relation to dopaminergic neurotransmission. In: Lajtha A (ed) Handbook of neurochemistry. Plenum, New York
79. Youdim MBH, Riederer P (2002) Iron in the brain, normal and pathological. In: Smitt A, Adelman G (eds) Encyclopedia of neuroscience. Elsevier Science BV, Amsterdam
80. Youdim MBH, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann NY Acad Sci 890: 7-25